CA2370030C - Sodium channel blocker compositions and the use thereof - Google Patents

Sodium channel blocker compositions and the use thereof Download PDF

Info

Publication number
CA2370030C
CA2370030C CA002370030A CA2370030A CA2370030C CA 2370030 C CA2370030 C CA 2370030C CA 002370030 A CA002370030 A CA 002370030A CA 2370030 A CA2370030 A CA 2370030A CA 2370030 C CA2370030 C CA 2370030C
Authority
CA
Canada
Prior art keywords
agent
gabapentin
sodium channel
pregabalin
chronic pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002370030A
Other languages
English (en)
French (fr)
Other versions
CA2370030A1 (en
Inventor
Nancy C. Lan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of CA2370030A1 publication Critical patent/CA2370030A1/en
Application granted granted Critical
Publication of CA2370030C publication Critical patent/CA2370030C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002370030A 1999-04-09 2000-04-10 Sodium channel blocker compositions and the use thereof Expired - Fee Related CA2370030C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12854399P 1999-04-09 1999-04-09
US60/128,543 1999-04-09
PCT/US2000/009387 WO2000061188A1 (en) 1999-04-09 2000-04-10 Sodium channel blocker compositions and the use thereof

Publications (2)

Publication Number Publication Date
CA2370030A1 CA2370030A1 (en) 2000-10-19
CA2370030C true CA2370030C (en) 2007-08-14

Family

ID=22435837

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002370030A Expired - Fee Related CA2370030C (en) 1999-04-09 2000-04-10 Sodium channel blocker compositions and the use thereof

Country Status (9)

Country Link
US (3) US20020037926A1 (https=)
EP (1) EP1169060B1 (https=)
JP (1) JP2002541215A (https=)
AT (1) ATE303162T1 (https=)
AU (1) AU4334900A (https=)
CA (1) CA2370030C (https=)
DE (1) DE60022333T2 (https=)
DK (1) DK1169060T3 (https=)
WO (1) WO2000061188A1 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60022333T2 (de) * 1999-04-09 2006-07-06 Euro-Celtique S.A. Natrium kanalblocker zusammensetzungen und deren verwendung
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
IL160523A0 (en) 2001-09-03 2004-07-25 Newron Pharm Spa PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
US20030124174A1 (en) * 2001-10-25 2003-07-03 Endo Pharmaceuticals, Inc Method for treating non-neuropathic pain
BRPI0200751B1 (pt) * 2002-02-06 2018-10-23 Univ Minas Gerais complexos de inclusão de benzaldeído semicabazona em ciclodextrinas e seu método de preparação
WO2003072751A2 (en) 2002-02-25 2003-09-04 Vanderbilt University Expression system for human brain-specific voltage-gated sodium channel, type 1
BR0317253A (pt) * 2002-12-13 2005-11-01 Warner Lambert Co Derivados pregabalina para o tratamento da fibromialgia e outras patologias
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
DE10332487A1 (de) * 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen
DE10359335A1 (de) * 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
US20050112183A1 (en) * 2003-11-25 2005-05-26 Galer Bradley S. Compositions and methods for treating neuropathic sensory loss
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
ITMI20041447A1 (it) * 2004-07-20 2004-10-20 Zambon Spa Composizione farmaceutica comprendente gabapentina
US8410149B2 (en) 2004-12-06 2013-04-02 Siga Technologies Inc. Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
CA2590962A1 (en) * 2004-12-06 2006-06-15 Siga Technologies, Inc. Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
US7994221B2 (en) 2004-12-06 2011-08-09 Siga Technologies, Inc. Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
EP1963280B1 (en) 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
WO2007120485A2 (en) * 2006-03-30 2007-10-25 Cinergen, Llc Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2008073257A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
CN101034257B (zh) * 2007-04-06 2010-09-08 上海复旦天臣新技术有限公司 用于全息记录的感光薄膜及其制备方法
US20100249238A1 (en) * 2007-07-02 2010-09-30 Ruben Dario Sinisterra Pharmaceutical compositions comprising semicarbazones and thiosemicarbazones and method for treating inflammatory, painful and febrile conditions and preventing signs and symptoms of inflammation
CN102908339A (zh) * 2007-11-23 2013-02-06 格吕伦塔尔有限公司 他喷他多组合物
JP2010043063A (ja) * 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
CN102892454B (zh) * 2010-01-26 2016-01-20 迈克尔·A·埃文斯 用于去神经支配的方法、装置以及药剂
JP2013531687A (ja) 2010-07-16 2013-08-08 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリジン化合物
EP2616441B1 (en) 2010-09-17 2019-08-07 Purdue Pharma L.P. Pyridine compounds and the uses thereof
EP2625169B1 (en) 2010-10-05 2015-03-25 Purdue Pharma L.P. Quinazoline compounds as sodium channel blockers
US20130189354A1 (en) * 2010-10-07 2013-07-25 Trinity Laboratories, Inc., Novel Pharmaceutical Compositions for Treating Chronic Pain and Pain Associated with Neuropathy
CN103429571A (zh) 2010-12-22 2013-12-04 普渡制药公司 作为钠通道阻断剂的取代吡啶
WO2013030665A1 (en) 2011-09-02 2013-03-07 Purdue Pharma L.P. Pyrimidines as sodium channel blockers
AU2012321111A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
WO2013064883A1 (en) 2011-10-31 2013-05-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
US9133131B2 (en) 2011-11-15 2015-09-15 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
WO2013136170A1 (en) 2012-03-16 2013-09-19 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
WO2014096941A1 (en) 2012-12-20 2014-06-26 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
WO2014112152A1 (ja) 2013-01-18 2014-07-24 有限会社ケムフィズ 神経因性疾病の治療のための医薬
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
US9637458B2 (en) 2013-03-04 2017-05-02 Jeffrey Lockman Pyrimidine carboxamides as sodium channel blockers
CA3082427A1 (en) 2013-03-15 2014-09-25 Purdue Pharma L.P. Carboxamide derivatives and use thereof
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
WO2015031036A1 (en) 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5] decane derivatives and use thereof
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
US9745287B2 (en) 2013-12-20 2017-08-29 Purdue Pharma L.P. Pyrimidines and use thereof
AU2014370407B2 (en) 2013-12-23 2018-03-29 Purdue Pharma L.P. Indazoles and use thereof
US9695144B2 (en) 2013-12-23 2017-07-04 Purdue Pharma L.P. Dibenzazepine derivatives and use thereof
EP3089978B1 (en) 2013-12-30 2018-08-29 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
US10047075B2 (en) 2014-01-24 2018-08-14 Purdue Pharma L.P. Pyridines and pyrimidines and use thereof
US10738026B2 (en) 2014-02-12 2020-08-11 Purdue Pharma L.P. Isoquinoline derivatives and use thereof
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
CA2948144A1 (en) 2014-05-06 2015-11-12 Purdue Pharma L.P. Benzomorphan analogs and use thereof
EP3154972A4 (en) 2014-06-13 2017-11-22 Purdue Pharma L.P. Azamophinan derivatives and use thereof
WO2015192039A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Heterocyclic morphinan derivatives and use thereof
US9958464B2 (en) * 2015-03-03 2018-05-01 Ark Diagnostics, Inc. Pregabalin immunoassays
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
JP2024509372A (ja) * 2021-02-26 2024-03-01 ヴァイルマ インコーポレイテッド ガバペンチノイドの局所投与のための方法及び製剤
CN115554293A (zh) * 2021-07-01 2023-01-03 南京宁丹新药技术有限公司 一种药物组合物及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US549692A (en) * 1895-11-12 And albert s
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DD151309A5 (de) * 1979-06-01 1981-10-14 Wellcome Found Verfahren zur herstellung von substituierten aminotriazinen
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
FR2639225B1 (fr) * 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
US5330515A (en) * 1992-06-17 1994-07-19 Cyberonics, Inc. Treatment of pain by vagal afferent stimulation
US5256669A (en) * 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
GB9306899D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation
GB9306886D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
GB9426102D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
US5741818A (en) * 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US5795864A (en) * 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
GB9515412D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
CA2264182A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
AU4031697A (en) 1996-08-29 1998-03-19 Takeda Chemical Industries Ltd. Cyclic ether compounds as sodium channel modulators
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
EP1829539A3 (en) 1996-11-05 2008-02-20 HEADEXPLORER ApS A method for treating tension-type headache
US6207685B1 (en) * 1996-12-06 2001-03-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Therapeutic application of a thienycyclohexylamine derivative
FR2756738B1 (fr) * 1996-12-06 1999-02-12 Sod Conseils Rech Applic Nouvelle application therapeutique d'un derive de la thienylcyclohexylamine
IL119890A (en) 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
GB9706730D0 (en) 1997-04-03 1997-05-21 Pharmacia & Upjohn Spa 2-[(3-substituted)-5-Isoxazolymethylaminojalkanamid derivatives
NZ500590A (en) * 1997-04-22 2001-11-30 Cocensys Inc Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
US5942530A (en) * 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
WO1999012537A1 (en) * 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
EP2201945B1 (en) 1997-11-21 2013-03-06 Purdue Neuroscience Company Use of substituted 2-aminoacetamides for treating or ameliorating anxiety
DE19802327A1 (de) 1998-01-23 1999-07-29 Goedecke Ag Synergistische Arzneimittelzubereitung mit analgetischer Wirkung
CA2309354A1 (en) 1998-01-23 1999-07-29 Leslie Magnus-Miller Gabapentin and its derivatives for the treatment of muscular and skeletal pain
US5905069A (en) * 1998-01-26 1999-05-18 The General Hospital Corporation Methods of decreasing or preventing pain using spicamycin or derivatives thereof
WO1999039712A1 (en) 1998-02-04 1999-08-12 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9804885D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
ES2137137B1 (es) 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
EP1093366B1 (en) 1998-07-09 2004-10-13 Warner-Lambert Company LLC Pharmaceutical composition containing gaba analogs and an antiviral agent to treat shingles
EP1094817A1 (en) 1998-07-09 2001-05-02 Warner-Lambert Company Compositions comprising gaba analogs and caffeine
US6281211B1 (en) * 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
CA2368631A1 (en) * 1999-03-26 2000-10-05 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
DE60022333T2 (de) * 1999-04-09 2006-07-06 Euro-Celtique S.A. Natrium kanalblocker zusammensetzungen und deren verwendung
NZ527771A (en) * 1999-08-04 2005-04-29 Icagen Inc Methods for treating or preventing anxiety
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
IL160523A0 (en) 2001-09-03 2004-07-25 Newron Pharm Spa PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE

Also Published As

Publication number Publication date
DE60022333D1 (de) 2005-10-06
AU4334900A (en) 2000-11-14
US20020037926A1 (en) 2002-03-28
US20080318932A1 (en) 2008-12-25
WO2000061188A9 (en) 2002-02-14
ATE303162T1 (de) 2005-09-15
DE60022333T2 (de) 2006-07-06
EP1169060B1 (en) 2005-08-31
CA2370030A1 (en) 2000-10-19
DK1169060T3 (da) 2006-01-16
EP1169060A1 (en) 2002-01-09
WO2000061188A1 (en) 2000-10-19
JP2002541215A (ja) 2002-12-03
US20040054005A1 (en) 2004-03-18
US7393872B2 (en) 2008-07-01

Similar Documents

Publication Publication Date Title
CA2370030C (en) Sodium channel blocker compositions and the use thereof
JP2002541215A5 (https=)
US6281211B1 (en) Substituted semicarbazides and the use thereof
US6335354B2 (en) Aminopyridines and methods of using thereof
EP1483247B1 (en) Aryl substituted pyrimidines and the use thereof
US7169782B2 (en) Aryl substituted thiazolidinones and the use thereof
ES2398093T3 (es) Pirazoles, triazoles y tetrazoles sustituidos con arilo como bloqueantes de los canales de sodio
AU2001249610A1 (en) Aminopyridines and their use as anticonvulsants and sodium channel blockers
AU754681B2 (en) Substituted semicarbazides and the use thereof
US6417220B2 (en) Mitochondrial membrane stabilizer
AU2002327243A1 (en) ARYL substituted thiazolidinones and the use thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150410